In Brief: United States Surgical/Alexion
This article was originally published in The Gray Sheet
Executive Summary
United States Surgical/Alexion: USSC gains exclusive worldwide manufacturing, marketing and sales rights to Alexion's genetically engineered pig organs for xenotransplantation. Alexion, in return, receives a 9.5% equity investment from U.S. Surgical, a commitment from USSC to contribute to further research and a royalty agreement on future sales...